Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

Posted on by

This milestone marks transition of Perfuse Therapeutics to a clinical-stage company SAN FRANCISCO, April 4, 2023 /PRNewswire/ — Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the US…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.